Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
5.8.2021 16:00:00 EEST | Business Wire | Press release
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, greatly enhances patient enrollment with a focus on representative trial participants.
Trialbee HIVE™ is a real-world data-driven patient matching platform that accelerates recruitment using global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Both companies are industry leaders in applying technology and data science to help clinical research sponsors succeed in the development of life-changing therapies. Precision has comprehensive study experience in complex therapeutic area and a converged approach to development that includes seamless operations between labs, data, and trials.
“We are working with life science innovators who share a passion to connect next generation treatments with the patients who need them most,” said Precision for Medicine President, Chad Clark. “This partnership expands our ability to reach more patients, faster; particularly those with rare or difficult-to-treat diseases.”
Precision for Medicine and Trialbee also reduce the burden on patients and sites. Trialbee’s patient data, which is HIPPA compliant, includes socioeconomic data as well as clinical data, enabling better characterization of the patient population. This helps Precision for Medicine forecast situations in which decentralized clinical trial approaches may be implemented to accommodate work schedules or when the use of free transportation services to and from the site can increase enrollment and retention.
“Our combined capabilities support a patient-first approach that will expand diversity, bolster enrollment, and speed the development of new therapies for complex diseases,” said Trialbee’s CEO, Matt Walz. “Our ability to bring more transparency and easy communication to the well-established Precision framework improves the potential for life-saving drugs to get to market and improve patient outcomes.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe. For more information, visit http://www.precisionformedicine.com.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005145/en/
Contact information
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
Louis Landon
Precision Medicine Group
310 984 7707
louis.landon@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International and Bank Partners Achieve Real-Time Cross-Bank Liquidity Management through Tokenised Deposits via CeBM under HKMA’s Ensemble TX3.11.2026 06:10:00 EET | Press release
Following the Hong Kong Monetary Authority’s (HKMA) announcement on interbank settlement of tokenised deposit transactions under EnsembleTX, Ant International announced that it has achieved real-time cross-bank liquidity management with its key banking partners as part of its active participation in EnsembleTX. In close collaboration with Bank of China (Hong Kong) (“BOCHK”, SEHK: 2388), China Construction Bank (Asia) (“CCB (Asia)”) and HSBC (SEHK: 5), Ant International successfully completed a series of live HKD interbank transactions between September and October 2026: BOCHK interbank transactions with CCB (Asia) CCB (Asia) interbank transactions HSBC interbank transactions Executed using tokenised deposit settled through the HKMA’s Central Bank Money (CeBM), the transfers were initiated via Ant International’s proprietary blockchain-based wholesale settlement platform, WhaleRTP. The transactions were near-instant, moving seamlessly from payment instruction to final receipt within fiv
SuperElastic* Material Unveiled by Angelalign2.11.2026 19:46:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other treatments,“ said Fox Hu, CEO of Angel. MC-SE will be available globally
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 19:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise spanning consumer-facing businesses, healthcare, medtech and life sciences. As Galderma advances its ambition to become the undisputed dermatology powerhouse, spanni
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 16:35:00 EET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 16:00:00 EET | Press release
Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contributing. As AI accelerates campaign execution, the quality of each decision matters more.” Intelligence Pro combines four capabilities within Smartly’s platform: Reach Planner helps teams comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom